Professor David I. Marks - Antibody Therapy in Acute Leukemia: Understanding Clinical Considerations for Use in Conjunction With HSCT - a podcast by PVI, PeerView Institute for Medical Education
from 2022-05-04T02:14:22.776234
Go online to PeerView.com/BYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity Professor David I. Marks, Farhad Ravandi, MD, and Matthias Stelljes, MD, give insights on the evidence behind the emergence of antibody therapy and its use in conjunction with HSCT in AML and ALL. These scientific MasterClass sessions are paired with a case-centered segment that illustrates therapeutic nuances such as the identification of transplant-eligible patients who may benefit from antibody-enhanced treatment protocols and the management of safety considerations unique to the use of antibodies in HSCT populations. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction/consolidation, pretransplant conditioning, or other roles in conjunction with transplant in the acute leukemia setting, Summarize updated evidence surrounding innovative antibody-based approaches to induction/consolidation, conditioning, or post-HSCT therapy in patients with AML or ALL, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HSCT for patients with AML or ALL, Manage safety considerations related to the use of antibody therapy in transplant-eligible populations with acute leukemia.
Further episodes of PeerView Immunology
Further podcasts by PVI, PeerView Institute for Medical Education